Skip to main content
main-content

GLP-1 receptor agonists


Browse the latest news, expert commentary, and educational content on the GLP-1 receptor agonist medication class.


Highlights

04-08-2021 | Stroke | News

Genetic analysis backs causal link between blood glucose and stroke

A Mendelian analysis supports a causal effect of hyperglycemia on stroke risk, and the researchers also pinpoint the medications most likely to reduce this risk.

03-23-2021 | Semaglutide | News

STEP 4: Long-term treatment needed for full semaglutide benefit

People with obesity continue to lose weight if they remain on semaglutide 2.4 mg after an initial 20 weeks of treatment, but gradually regain it if they switch to placebo, show the STEP 4 findings.

03-23-2021 | Semaglutide | Commentary | Article

STEP 4: Long-term semaglutide treatment combats weight regain

Domenica Rubino discusses the chronicity of obesity, and how STEP 4 demonstrates the need for long-term semaglutide treatment to avoid weight regain (5:59).

Semaglutide for weight loss: The STEP and SELECT trials

Get the latest results and insights from the researchers.

More on GLP-1 receptor agonists

Stay informed with Medicine Matters

Get the latest developments in diabetes delivered straight to your inbox

Image Credits